What is Leerink Partnrs’ Forecast for EWTX FY2026 Earnings?

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) – Equities researchers at Leerink Partnrs raised their FY2026 earnings per share (EPS) estimates for shares of Edgewise Therapeutics in a research report issued on Monday, December 16th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($1.91) per share for the year, up from their prior forecast of ($2.04). The consensus estimate for Edgewise Therapeutics’ current full-year earnings is ($1.45) per share.

Edgewise Therapeutics (NASDAQ:EWTX) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.01.

A number of other brokerages have also recently issued reports on EWTX. Piper Sandler raised their price objective on Edgewise Therapeutics from $48.00 to $51.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Evercore ISI raised their price target on Edgewise Therapeutics from $45.00 to $50.00 and gave the stock an “outperform” rating in a research report on Tuesday. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $32.00 price target on shares of Edgewise Therapeutics in a research note on Tuesday, September 17th. Wedbush increased their price objective on Edgewise Therapeutics from $44.00 to $45.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. Finally, Truist Financial lifted their target price on shares of Edgewise Therapeutics from $33.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, November 27th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $43.17.

Edgewise Therapeutics Stock Up 2.6 %

Shares of NASDAQ:EWTX opened at $30.80 on Thursday. The stock has a market cap of $2.92 billion, a PE ratio of -20.53 and a beta of 0.12. The company’s fifty day moving average is $32.83 and its 200 day moving average is $24.47. Edgewise Therapeutics has a 52 week low of $8.49 and a 52 week high of $38.12.

Insiders Place Their Bets

In other Edgewise Therapeutics news, General Counsel John R. Moore sold 20,922 shares of the business’s stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $27.63, for a total transaction of $578,074.86. Following the transaction, the general counsel now directly owns 3,252 shares of the company’s stock, valued at approximately $89,852.76. The trade was a 86.55 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 24.11% of the company’s stock.

Institutional Investors Weigh In On Edgewise Therapeutics

A number of large investors have recently modified their holdings of EWTX. Exome Asset Management LLC bought a new position in Edgewise Therapeutics in the third quarter worth about $1,599,000. Franklin Resources Inc. grew its stake in Edgewise Therapeutics by 84.2% in the third quarter. Franklin Resources Inc. now owns 45,223 shares of the company’s stock worth $1,207,000 after purchasing an additional 20,674 shares during the period. Barclays PLC raised its holdings in Edgewise Therapeutics by 291.0% in the third quarter. Barclays PLC now owns 119,350 shares of the company’s stock worth $3,186,000 after purchasing an additional 88,826 shares in the last quarter. Orion Portfolio Solutions LLC purchased a new position in Edgewise Therapeutics during the third quarter valued at $347,000. Finally, XTX Topco Ltd bought a new stake in shares of Edgewise Therapeutics during the 3rd quarter valued at $755,000.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.